Clinical trials have demonstrated that pertuzumab, when used in combination with trastuzumab and chemotherapy, can significantly improve progression-free survival and overall survival in patients with HER2-positive breast cancer. The addition of pertuzumab to standard treatment regimens has been shown to provide a synergistic effect, enhancing the overall therapeutic efficacy.
